scholarly journals Cardiac Involvement of Hepatitis B and C Virus Infection

2013 ◽  
Vol 8 (2) ◽  
pp. 113-118 ◽  
Author(s):  
Mohammad Saifullah Patwary ◽  
KMHS Sirajul Haque ◽  
Nusrat Shoaib ◽  
Khondaker Syedus Salehin ◽  
ATM Iqbal Hosan
Keyword(s):  
Heart Disease ◽  
Hepatitis C ◽  
Hepatitis B ◽  
Heart Diseases ◽  
Hepatocellular Cancer ◽  
Japanese Patients ◽  
Hcv Infection ◽  
Global Network ◽  
Middle Income ◽  
Number Of Patients

Hepatitis B virus (HBV) and Hepatitis C virus (HCV) are the cause of many different forms of heart disease worldwide and yet few cardiologists are aware of it as an etiology of heart disease, or its treatment. The burden of HBV and HCV derived heart diseases are global, with a higher prevalence in Asia, Africa, and low- and middle-income countries. The study showed that in more than 10% of Japanese patients, their cardiomyopathies are associated with HCV infection. More recently, it is found in the USA that up to 15% of patients with heart failure with myocarditis have been associated HCV infection. In contrast, in China 79% of patients with hepatocellular cancer and 37% of hepatitis C patients have heart disease, as detected by measuring a proven and sensitive biomarker of heart disease, NT-proBNP. In Pakistan, 17% of hepatitis C patients have heart diseases, as measured by this metric (NT-proBNP). Based on these data, 3% of 6.6 billion (198 million) persons worldwide are infected with HCV and 17–37% (34–73 million) persons are suffering from HCV-derived heart diseases. These figures may be comparable to the number of patients with hepatitis C. HCV infection causes only hepatitis in some patients, only heart diseases in some patients, and both hepatitis and heart diseases in other patients. A global network is required to establish methods to detect heart diseases caused by infectious agents. Other goals for the network are the expansion of preventive and therapeutic programs in under privileged countries. DOI: http://dx.doi.org/10.3329/uhj.v8i2.16084 University Heart Journal Vol. 8, No. 2, July 2012

High prevalence of occult hepatitis C virus infection in patients with chronic hepatitis B virus infection

2013 ◽  
Vol 62 (8) ◽  
pp. 1235-1238 ◽  
Author(s):  
Inmaculada Castillo ◽  
Javier Bartolomé ◽  
Juan Antonio Quiroga ◽  
Vicente Carreño
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B Virus ◽  
Virus Infection ◽  
Hepatitis B ◽  
Hcv Infection ◽  
Hbv Infection ◽  
Chronic Hepatitis B Virus ◽  
B Virus

Hepatitis C virus (HCV) infection in the absence of detectable antibodies against HCV and of viral RNA in serum is called occult HCV infection. Its prevalence and clinical significance in chronic hepatitis B virus (HBV) infection is unknown. HCV RNA was tested for in the liver samples of 52 patients with chronic HBV infection and 21 (40 %) of them were positive for viral RNA (occult HCV infection). Liver fibrosis was found more frequently and the fibrosis score was significantly higher in patients with occult HCV than in negative ones, suggesting that occult HCV infection may have an impact on the clinical course of HBV infection.

scholarly journals Association of Hepatocellular Carcinoma (HCC) With Hepatitis B Virus (HBV) Versus Hepatitis C Virus (HCV) Infection Among Different Asian Subgroups

2011 ◽  
Vol 140 (5) ◽  
pp. S-924-S-925 ◽  
Author(s):  
Hillary Lin ◽  
Nghiem B. Ha ◽  
Deawodi Ladzekpo ◽  
Aijaz Ahmed ◽  
Walid Ayoub ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Hcv Infection ◽  
B Virus

Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial

2013 ◽  
Vol 31 (32) ◽  
pp. 4067-4075 ◽  
Author(s):  
Ann-Lii Cheng ◽  
Yoon-Koo Kang ◽  
Deng-Yn Lin ◽  
Joong-Won Park ◽  
Masatoshi Kudo ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Hepatitis B ◽  
Hepatocellular Cancer ◽  
Progression Free Survival ◽  
Phase Iii ◽  
Severe Toxicity ◽  
Open Label ◽  
Phase Iii Trial ◽  
Open Label Phase ◽  
Hand Foot Syndrome

Purpose Open-label, phase III trial evaluating whether sunitinib was superior or equivalent to sorafenib in hepatocellular cancer. Patients and Methods Patients were stratified and randomly assigned to receive sunitinib 37.5 mg once per day or sorafenib 400 mg twice per day. Primary end point was overall survival (OS). Results Early trial termination occurred for futility and safety reasons. A total of 1,074 patients were randomly assigned to the study (sunitinib arm, n = 530; sorafenib arm, n = 544). For sunitinib and sorafenib, respectively, median OS was 7.9 versus 10.2 months (hazard ratio [HR], 1.30; one-sided P = .9990; two-sided P = .0014); median progression-free survival (PFS; 3.6 v 3.0 months; HR, 1.13; one-sided P = .8785; two-sided P = .2286) and time to progression (TTP; 4.1 v 3.8 months; HR, 1.13; one-sided P = .8312; two-sided P = .3082) were comparable. Median OS was similar among Asian (7.7 v 8.8 months; HR, 1.21; one-sided P = .9829) and hepatitis B–infected patients (7.6 v 8.0 months; HR, 1.10; one-sided P = .8286), but was shorter with sunitinib in hepatitis C–infected patients (9.2 v 17.6 months; HR, 1.52; one-sided P = .9835). Sunitinib was associated with more frequent and severe adverse events (AEs) than sorafenib. Common grade 3/4 AEs were thrombocytopenia (29.7%) and neutropenia (25.7%) for sunitinib; hand-foot syndrome (21.2%) for sorafenib. Discontinuations owing to AEs were similar (sunitinib, 13.3%; sorafenib, 12.7%). Conclusion OS with sunitinib was not superior or equivalent but was significantly inferior to sorafenib. OS was comparable in Asian and hepatitis B–infected patients. OS was superior in hepatitis C–infected patients who received sorafenib. Sunitinib-treated patients reported more frequent and severe toxicity.

scholarly journals The direct-medical costs associated with interferon-based treatment for Hepatitis C in Vietnam

2020 ◽  
Vol 4 ◽  
pp. 129
Author(s):  
Huyen Anh Nguyen ◽  
Graham S. Cooke ◽  
Jeremy N. Day ◽  
Barnaby Flower ◽  
Le Thanh Phuong ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Treatment Regimen ◽  
Medical Costs ◽  
Hcv Infection ◽  
Economic Evaluations ◽  
Middle Income ◽  
Total Cost ◽  
Middle Income Countries ◽  
Direct Medical Costs ◽  
Ifn Treatment

Background: Injectable interferon-based therapies have been used to treat hepatitis C virus (HCV) infection since 1991. International guidelines have now moved away from interferon-based therapy towards direct-acting antiviral (DAA) tablet regimens, because of their superior efficacy, excellent side-effect profiles, and ease of administration. Initially DAA drugs were prohibitively expensive for most healthcare systems. Access is now improving through the procurement of low-cost, generic DAAs acquired through voluntary licenses. However, HCV treatment costs vary widely, and many countries are struggling with DAA treatment scale-up. This is not helped by the limited cost data and economic evaluations from low- and middle-income countries to support HCV policy decisions. We conducted a detailed analysis of the costs of treating chronic HCV infection with interferon-based therapy in Vietnam. Understanding these costs is important for performing necessary economic evaluations of novel treatment strategies. Methods: We conducted an analysis of the direct medical costs of treating HCV infection with interferon alpha (IFN) and pegylated-interferon alpha (Peg-IFN), in combination with ribavirin, from the health sector perspective at the Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam, in 2017. Results: The total cost of the IFN treatment regimen was estimated to range between US$1,120 and US$1,962. The total cost of the Peg-IFN treatment regimen was between US$2,156 and US$5,887. Drug expenses were the biggest contributor to the total treatment cost (54-89%) and were much higher for the Peg-IFN regimen. Conclusions: We found that treating HCV with IFN or Peg-IFN resulted in significant direct medical costs. Of concern, we found that all patients incurred substantial out-of-pocket costs, including those receiving the maximum level of support from the national health insurance programme. This cost data highlights the potential savings and importance of increased access to generic DAAs in low- and middle-income countries and will be useful within future economic evaluations.

scholarly journals Trends in Prevalence of Hepatitis B (HBV) and Hepatitis C (HCV) virus infection among blood donors in Apollo Hospital, Dhaka, Bangladesh, 2007-2011

Pulse ◽  
2014 ◽  
Vol 6 (1-2) ◽  
pp. 27-32 ◽  
Author(s):  
KM Huda ◽  
TA Nasir
Keyword(s):  
Hepatitis C ◽  
Hepatitis B ◽  
Blood Donors ◽  
Hepatitis B Surface Antigen ◽  
Public Health Problem ◽  
Hcv Infection ◽  
Infection Prevalence ◽  
Major Public Health Problem ◽  
Transmitted Infection ◽  
Recruitment And Selection

Transfusion transmitted infection (TTIs) is still a concern associated with blood transfusion as hepatitis B and hepatitis C remains a major public health problem in a country like Bangladesh. The trends of the prevalence of HBsAg and HCV infection among the healthy blood donors even in a tertiary level hospital could be a guide for planning and implementing programs for preventive measures. All samples of a total 18,381 unit of blood were screened for hepatitis B surface antigen and anti-hepatitis C virus antibodies at Apollo Hospitals Dhaka over a period of 5 years (2007-2011). The prevalence of HBV and HCV infection was calculated by year to demonstrate the trends. The overall sero prevalence rate of HBV and HCV among all blood donors at Apollo Hospitals, Dhaka during 2007 to 2011 was 1.42% and 0.10% respectively. There was decreasing trend observed in sero prevalence of HBV (1.77% vs 1.64%) and HCV (0.13% vs 0.02%) over five years of time, although this change was not statistically significant (p=0.16 for HBV and p=0.20 for HCV). However, a significant decreasing trend was observed in the sero prevalence of HBV among blood donors aged 30 years and above, which was 1.04% in 2011 against 1.73% in 2007 (p=0.04). The decreasing trend in the prevalence of HBV and HCV infection might be the result of improvement in donor recruitment and selection, replacement donation exclusion in transfusion services, and possibly decreasing HBV infection prevalence in general population. DOI: http://dx.doi.org/10.3329/pulse.v6i1-2.20330 Pulse Vol.6 January-December 2013 p.27-32

scholarly journals Study of heart disease in pregnancy and its effect on maternal outcome

2019 ◽  
Vol 8 (8) ◽  
pp. 3031
Author(s):  
Nitin Kumar Jain ◽  
Shabana Sultan
Keyword(s):  
Heart Disease ◽  
Maternal Mortality ◽  
Heart Diseases ◽  
Functional Class ◽  
Maternal Outcome ◽  
Class Iii ◽  
Nyha Functional Class ◽  
Number Of Patients ◽  
Heart Disease In Pregnancy ◽  
In Pregnancy

Background: Heart diseases in pregnant women and has higher incidence of maternal mortality and morbidity and is regarded as risk factor for unfavourable outcome of pregnancy both for the mother and the foetus. Heart disease in pregnancy was found to be second indirect cause contributing to maternal mortality in India.Methods: This study is a hospital based prospective analytical study carried out in the Department of Obstetrics and Gynaecology, Sultania Zanana Hospital, Gandhi Medical College, Bhopal over a period of 1 year from 1st March 2017 to 28th February 2018. Patients were evaluated clinically by both obstetrician and cardiologist and followed all through their hospital stay till discharge.Results: Total 51 cases of heart disease were found during the study period. Incidence of heart disease in our study during study period was found 0.25%. Most patients were unbooked 33(64.71%) and maximum number of patients belonged to NYHA functional class II 24 (47.06%), RHD cases were 4 times more common than CHD. 24 (47.06%) patients had undergone surgical intervention for heart disease. Congestive cardiac failure was most common complication seen. Three maternal deaths were seen. All cases belonged to NYHA functional class III. All 3 cases were unbooked presented first time in labor.Conclusions: We found that pregnancy outcome was good in booked cases with regular checkup by obstetrician and cardiologist, surgically corrected cases and those with NYHA functional class I and II. Hence, joint management by obstetrician, cardiologist, and anesthetist is required to ensure better maternal outcome.

Sign in / Sign up

Export Citation Format

Share Document